NCT02157389

Brief Summary

Placebo and nocebo responses have mainly been studied in healthy humans for pharmacological rather than psychological interventions. Moreover, only few studies examined patients or tested how previous experience and attitudes affect placebo and nocebo responses. On the psychological level expectancy and classical conditioning have been identified as two primary mechanisms. Both seem to be important with classical conditioning potentially having more long-term effects and expectancy being more important in nocebo effects. There is some initial evidence from the investigators own research that patients may be more prone to these effects and the investigators have also shown that placebo effects may last up to several years after treatment. The investigators therefore examine previous attitudes to pharmacological interventions for chronic pain in patients with chronic back pain and subdivide them into groups with high of low belief in the respective treatment modality. The investigators then apply a pharmacological placebo and study the interaction between the prevailing attitude (implicit and explicit) and the placebo effect with respect to pain perception but also to neurobiological mechanisms using functional magnetic resonance imaging. In addition to expectancy, conditioning of placebo will be examined and the long-term effects of the intervention will be determined.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2012

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2012

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

June 3, 2014

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 6, 2014

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2014

Completed
Last Updated

January 16, 2015

Status Verified

January 1, 2015

Enrollment Period

2.4 years

First QC Date

June 3, 2014

Last Update Submit

January 15, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Changes in pain intensity and pain unpleasantness ratings after placebo intervention

    immediatey to one week

Secondary Outcomes (2)

  • Changes in neuronal activity in response to painful stimulation after placebo administration

    immediately

  • Changes in movement abilities after placebo administration

    immediately to one week

Study Arms (1)

placebo

EXPERIMENTAL

Administration of a pharmacological placebo (sodium chloride) via transdermal application to investigate the influence on pain perception in chronic back pain patients and to investigate the influence of attitude and experience with medication on the placebo effect

Other: Administration of a pharmacological placebo

Interventions

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male and female human subjects with chronic back pain (chronic persistent and recurrent pain \> 6 months)
  • Age between 18 and 65
  • Voluntary participation.

You may not qualify if:

  • Acute or chronic somatic diseases and inflammatory, neuropathic or tumor-related pain
  • Acute and chronic mental disorders according to DSM-IV (except for comorbid anxiety or depression, which are frequent in chronic pain)
  • Insufficient German language skills
  • Cognitive limitations
  • Intake of opioid medication or tranquilizers
  • Metal implants or electric implants that cannot be removed
  • Pregnancy
  • Claustrophobia
  • History of epilepsy, brain trauma, or brain tumor

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Central Institute of Mental Health

Mannheim, 68159, Germany

Location

Study Officials

  • Herta Flor, PhD

    Medical Faculty Mannheim, Heidelberg University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr. Herta Flor

Study Record Dates

First Submitted

June 3, 2014

First Posted

June 6, 2014

Study Start

July 1, 2012

Primary Completion

December 1, 2014

Study Completion

December 1, 2014

Last Updated

January 16, 2015

Record last verified: 2015-01

Locations